Kian Behbakht
Overview
Explore the profile of Kian Behbakht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1956
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villagomez F, Lang J, Nunez-Avellaneda D, Behbakht K, Dimmick H, Webb P, et al.
Cancer Res Commun
. 2024 Dec;
5(1):39-53.
PMID: 39625235
High-grade serous ovarian carcinoma is marked by chromosomal instability, which can serve to promote disease progression and allow cancer to evade therapeutic insults. The report highlights the role of claudin-4...
2.
Liu J, Berchuck A, Backes F, Cohen J, Grisham R, Leath C, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):512-519.
PMID: 39413835
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of...
3.
Villagomez F, Lang J, Nunez-Avellaneda D, Behbakht K, Dimmick H, Webb P, et al.
bioRxiv
. 2024 Sep;
PMID: 39282307
During cancer development, the interplay between the nucleus and the cell cycle leads to a state of genomic instability, often accompanied by observable morphological aberrations. These aberrations can be controlled...
4.
Nguyen L, Watson Z, Ortega R, Woodruff E, Jordan K, Iwanaga R, et al.
Mol Cancer Res
. 2024 Aug;
22(12):1117-1127.
PMID: 39136655
Poly ADP-ribose polymerase inhibitors (PARPi) are first-line maintenance therapy for ovarian cancer and an alternative therapy for several other cancer types. However, PARPi-resistance is rising, and there is currently an...
5.
Van Kleunen L, Ahmadian M, Post M, Wolsky R, Rickert C, Jordan K, et al.
Cancer Immunol Res
. 2024 Aug;
12(11):1492-1507.
PMID: 39115368
Ovarian cancer is the deadliest gynecologic malignancy, and therapeutic options and mortality rates over the last three decades have largely not changed. Recent studies indicate that the composition of the...
6.
Nguyen L, Watson Z, Ortega R, Woodruff E, Jordan K, Iwanaga R, et al.
Mol Cancer Ther
. 2024 Jun;
:OF1-OF16.
PMID: 38863225
Despite the success of poly-ADP-ribose polymerase inhibitors (PARPi) in the clinic, high rates of resistance to PARPi presents a challenge in the treatment of ovarian cancer, thus it is imperative...
7.
Nguyen L, Watson Z, Ortega R, Woodruff E, Jordan K, Iwanaga R, et al.
Mol Cancer Ther
. 2024 May;
PMID: 38714351
Despite the success of Poly-ADP-ribose polymerase inhibitors (PARPi) in the clinic, high rates of resistance to PARPi presents a challenge in the treatment of ovarian cancer, thus it is imperative...
8.
Dexter J, Brubaker L, Bitler B, Goff B, Menon U, Moore K, et al.
Gynecol Oncol Rep
. 2024 Apr;
53:101376.
PMID: 38590930
Early diagnosis and screening of ovarian cancer remain significant challenges to improving patient outcomes. There is an urgent need to implement both established and modern strategies to address the "early...
9.
Van Kleunen L, Ahmadian M, Post M, Wolsky R, Rickert C, Jordan K, et al.
bioRxiv
. 2024 Feb;
PMID: 38352574
Despite ovarian cancer being the deadliest gynecological malignancy, there has been little change to therapeutic options and mortality rates over the last three decades. Recent studies indicate that the composition...
10.
Greenwood A, Woodruff E, Nguyen C, Piper C, Clauset A, Brubaker L, et al.
Obstet Gynecol
. 2024 Jan;
143(3):e63-e77.
PMID: 38176019
Objective: To determine biomarkers other than CA 125 that could be used in identifying early-stage ovarian cancer. Data Sources: Ovid MEDLINE ALL, EMBASE, Web of Science Core Collection, ScienceDirect, Clinicaltrials.gov...